Advances in nutrition (Bethesda, Md.)

Nutritional Issues with Incretin-Based Medications for Obesity and What They Mean for Treatment

Updated

Abstract

Incretin-based obesity management medications (OMMs) may lead to significant weight loss but also present potential nutritional challenges.

  • Weight reduction effects from incretin-based OMMs are accompanied by gastrointestinal disturbances and possible loss of lean body mass.
  • Nutritional challenges could reduce energy expenditure and increase risks of rebound weight gain, sarcopenia, and frailty.
  • These medications can suppress energy intake but may negatively impact diet quality and macronutrient distribution.
  • There is a potential risk of vitamin and mineral deficiencies and disordered eating behaviors associated with OMMs.
  • Specific dietary and behavioral strategies, like higher protein intake and resistance training, may help counteract these nutritional challenges.
  • The effectiveness of these strategies as adjunct treatments to OMMs remains unclear.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflict of interest TBP and SSD are members of the Communication and Development committee of the International Federation for the Surgery of Obesity and Metabolic Disorders, European chapter (IFSO-EC), which does not have any financial support or any relationship to the current article. All other authors have no conflicts of interest to declare. SSD and AB received research funding from Novo Nordisk. CJM is supported by the scholarship of Fullbright fellowship for excellence scholars. The supporting sources had no involvement in the writing of this paper or any restrictions regarding the submission of the article for publication.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free